Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

206.64 +0.75 (+0.36%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

July 15, 2025

Via Benzinga

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

June 30, 2025

From Summit Therapeutics Inc.

Via Business Wire

Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds ↗

June 24, 2025

Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

A Glimpse of Revolution Medicines's Earnings Potential ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Top 3 Health Care Stocks That Could Blast Off In December ↗

December 04, 2024

Via Benzinga

Revolution Medicines Inc. (NASDAQ: RVMD) Climbs to New 52-Week High

April 10, 2024

Via Investor Brand Network

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma ↗

June 24, 2025

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured...

Via Stocktwits

Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday ↗

May 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 07, 2025

Via Benzinga

Revolution Medicines's Earnings: A Preview ↗

February 23, 2024

Via Benzinga

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? ↗

April 28, 2025

Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.

Via Benzinga

Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates ↗

December 02, 2024

Via Benzinga

Topics Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 02, 2024

Via Benzinga

Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter ↗

July 16, 2024

Via Benzinga

Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

July 16, 2024

Via Benzinga

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 09, 2024

Via Benzinga

Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗

July 09, 2024

Via Benzinga

The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 ↗

June 08, 2024

Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 ↗

May 08, 2024

RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Top 3 Health Care Stocks That May Collapse In Q2 ↗

April 12, 2024

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 10, 2024

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.

Via Benzinga

What's Going On With Revolution Medicines Stock? ↗

April 10, 2024

Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The...

Via Benzinga

Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday ↗

April 10, 2024

U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.

Via Benzinga

Topics Stocks

Morgan Stanley Maintains Equal-Weight Rating for Revolution Medicines: Here's What You Need To Know ↗

March 08, 2024

Via Benzinga

Uncovering Noteworthy Technical Analysis Findings for REVOLUTION MEDICINES INC (NASDAQ:RVMD). ↗

February 01, 2024

A technical analysis of REVOLUTION MEDICINES INC.

Via Chartmill

Earnings Scheduled For February 26, 2024 ↗

February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.